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Objective: Our study uses data from a large clinical trial to further dissect the contributors 
attitude toward antipsychotic medication measured with the Drug Attitude Inventory (DAI) in 
schizophrenia.
Method: A total of 227 consecutive outpatients (140 males, 87 females) with schizophrenia 
or schizoaffective disorder according to DSM-IV criteria were evaluated. Structural equation 
models (SEM) were used to examine the relationship between attitudes toward medication as 
measured with the DAI and clinical variables assessed by Positive and Negative Syndrome 
Scale (PANSS) and Global Assessment of Functioning (GAF).
Results: Among four models, the data better fit a model in which attitudes toward medication 
(DAI-30) was predicted by PANSS Positive and Insight measures, and GAF (goodness-
of-fit = 0.99).
Conclusion: The data best fit a model where the most complex interaction of insight measures 
and positive symptoms does predict attitudes toward medication.
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Introduction
Schizophrenia is a chronic disease that requires long-term treatment. Adherence to the 
prescribed antipsychotic therapy is a crucial factor for a successful treatment outcome.1 
Therefore, the patient’s positive personal opinion towards the chosen treatment can 
facilitate a better compliance.2,3
Although a multitude of factors play a role in a patient’s decision as to whether 
or not to take medication, attitudes and beliefs about health and illness have been 
consistently identified as the major factors in such decisions. These attitudes and beliefs 
are better understood in the context of the health–belief model (HBM).4,5 Many of the 
recent instruments that are often in use for measuring subjective responses and serve 
as predictors of adherence invariably include items that tap into specific components 
of the HBM that has been shown to influence adherence behavior.6–12
‘Insight’ is another factor frequently implicated as a mediator in the patient 
adherence to drug prescriptions.13,14 Sajatovic and colleagues15 studied insight into 
illness and attitudes towards medications (ATM) among in-patients with schizophrenia 
and found that the antipsychotic (AP) treatment improved symptoms and insight 
into illness, but did not appreciably change ATM. Adverse AP effects also are not 
consistently associated with negative attitude while insight to the illness is increasingly 
associated with negative attitude toward medication13,15 so that other variables are 
needed to explain patients’ ATM.Patient Preference and Adherence 2009:3 306
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The current report is an analysis of data of a large sample 
of subjects with schizophrenia eligible to a risperidone 
long-acting trial,16 aimed to further dissect the contributors 
of attitude toward antipsychotic medication measured with 
the Drug Attitude Inventory (DAI). Several studies have 
reported that a wide range of clinical, psychopathological, 
and demographic variables predict ATM,7–15,17 however, 
these observations mainly report that the worse measures 
(eg, severity of illness and insight) predicted a worse ATM. 
We further hypothesized that the same variables could 
have different load to predict attitude toward medication 
on the basis of different pattern of interaction among them 
(ie, from less to more complex interaction). With this aim, we 
decided to use the structural equation model (SEM) analysis 
to explore the best fit of prediction of selected clinical and 
psychopathological variables (ie, Positive and Negative 
Syndrome Scale [PANSS] scores and Global Assessment of 
Functioning [GAF]) with a priori variation of relationship 
among the set of predictors, as stated by the researchers on 
the basis of the literature.7,17
Methods
A total of 227 consecutive outpatients (140 male, 87 female, 
mean age 49.91 ± 11.05 standard deviation [SD], range 
18–65) with schizophrenia or schizoaffective disorder 
according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM-IV) criteria,18 and who required long-term 
antipsychotic therapy were recruited. Diagnoses were made 
by a senior staff psychiatrist on the basis of clinical interview. 
At the time of recruitment, all patients were symptomati-
cally stable and had been taking the same dose of antipsy-
chotic agents for at least one month before the screening 
visit. Patients were considered stable if there had been no 
appreciable change in symptoms over the previous month, 
regardless of the severity of their symptoms. They were not 
considered to be either optimally treated or symptom-free. 
All these patients agreed to participate in a switching study 
to long-acting injectable risperidone and were effectively 
treated with long-acting risperidone. All patients or their 
legal representatives provided written informed consent to 
the study. Further information on this population is reported 
by Rossi and colleagues.16
Psychopathological evaluation
Symptom severity was assessed using the PANSS.19 Positive, 
negative, cognitive, and general psychopathology PANSS 
scores and ‘insight’ PANSS item were evaluated as reported 
by Daneluzzo and colleagues.20 Community functioning was 
evaluate using the GAF scale.21 Personal attitudes towards 
AP treatment was rated by a self-report questionnaire, the 
DAI-30 (see the Italian validation study for details).7,22 The 
DAI-30 is a valid and reliable tool used in clinical trials to 
investigate the patients’ opinion towards therapy. All these 
evaluations were performed before patients switched to 
long-acting risperidone.
statistical analysis
Structural equation models were used to examine the 
relationship between attitudes toward medication as measured 
with DAI and the clinical variables.
SEM is a statistical technique for testing and estimating 
causal relationships using a combination of statistical data 
and qualitative causal assumptions. The SEM is a statistical 
technique that combines elements of traditional multivariate 
models, such as regression analysis, factor analysis, and 
simultaneous equation modeling.23 The purpose is structure 
detection, ie, to examine the underlying (or latent) relation-
ships between the variables. SEM extraction methods go 
one step further by adding the assumption that some of the 
variability in the data cannot be explained by the compo-
nents (usually called factors in other extraction methods). 
As a result, the total variance explained by the solution is 
smaller; however, the addition of this structure to the factor 
model makes these methods ideal for examining relationships 
between the variables.
Since SEM is a confirmatory technique, the model must 
be specified correctly based on the type of analysis that the 
modeler is attempting to confirm. There are usually two 
main parts to SEM: the structural model showing potential 
causal dependencies between endogenous and exogenous 
variables and the measurement model showing the relations 
between the latent variables and their indicators. Parameter 
estimation is done by comparing the covariance matrices 
that represent the relationships between variables and the 
estimated covariance matrices of the best-fitting model. This 
is obtained through numerical maximization of a fit criterion 
as provided by maximum likelihood, weighted least squares, 
or asymptotically distribution-free methods. This is best 
accomplished by using a specialized SEM analysis program, 
SAS Proc CALIS (SAS Institute, Cary, NC).
In SAS Proc CALIS, when data fits the best model, 
the analysis will indicate minimum significant differences 
between the hypothesized model and the observed data. 
Model fit was assessed using the maximum-likelihood 
chi-squared test, the root mean square error of approximation 
(RMSEA), and by the comparison of the pair-wise correlation Patient Preference and Adherence 2009:3 307
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and covariance matrix with the estimates from the best-fit 
model.
The model we proposed in the study is based on the 
correlation matrix of three measures of psychotic symptoms 
(PANSS Positive, PANSS Negative, and PANSS General), 
two measures of insight (PANSS Item and PANSS Cognitive 
factors), one measure of GAF, and one measure of attitudes 
toward medication (DAI-30). We estimated this model 
by maximum likelihood, assessed its goodness-of-fit, and 
examined possible modifications of the model.
Results
Clinical features of the studied sample are reported in 
Table 1.
The hypothesized model 1 (Figure 1; Table 2 ), which 
assumes that all variables (PANSS Positive, PANSS 
Negative, PANSS General, PANSS Cognitive, PANSS G12, 
and GAF) are correlated with attitudes toward medication 
(DAI-30) had a satisfactory goodness-of-fit model. The 
goodness-of-fit statistics indicate the appropriateness of 
the linear structural equation model for the given dataset 
(covariance matrix; Goodness-of-Fit Index [GFI] = 0.68, 
maximum likelihood estimation fit function = 2.97, RMSEA 
estimate = 0.99).
The hypothesized model 2 (Figure 1; Table 2), which 
assumes that PANSS variables but not GAF are correlated with 
attitudes toward medication (DAI-30) also had a satisfactory 
goodness-of-fit model (GFI = 0.61, maximum likelihood 
estimation fit function = 3.43, RMSEA estimate = 1.31).
The hypothesized model 3 (Figure 1; Table 2), which 
assumes that all variables (PANSS Positive, PANSS Nega-
tive, PANSS General, PANSS Cognitive, PANSS Insight, 
and GAF) are correlated with attitudes toward medication 
(DAI-30) had a similar satisfactory goodness-of-fit 
model (GFI = 0.76, maximum likelihood estimation fit 
function = 3.49, RMSEA estimate = 0.83). In comparison 
to model 1, we added a possible relationship among the 
variables group “PANSS Positive, PANSS Negative, PANSS 
General” and among the variables group “PANSS Cognitive, 
PANSS Insight”.
The hypothesized model 4 assumes that the variables 
PANSS Positive, PANSS G12 and GAF are correlated with 
attitudes toward medication (DAI-30) (Figure 1; Table 2). 
In this model we added a possible relationship among the 
variables group “PANSS Positive, PANSS Negative, PANSS 
General” and among the variables group “PANSS Cognitive, 
PANSS Insight”. We observed a substantial increase in the 
GFI, a reduction in the maximum likelihood chi-squared test, 
and a reduction in the RMSEA, indicating a better model fit 
for model 4 compared with the previous models (GFI = 0.99, 
maximum likelihood estimation fit function = 0.005, 
RMSEA estimate = 0.02).
The maximum likelihood function is a function which 
reflects the difference between the observed and predicted 
by the model, covariance matrices. The more complex the 
model, the more likely a good fit. In a just-identified model, 
with as many parameters as possible while still achieving 
a solution, there will be a perfect fit. In comparison to the 
complexity of the proposed model 4 where the three PANSS 
subscales are singly considered and introduced in the model 
as single explanatory variables, the low sample size could 
be identified as a possible confounder in the reproducibility 
of the model.
Discussion
The issue of attitude toward medication in schizophrenia 
has gained increasing attention both for psychopathological 
and pharmacotherapeutic reasons.24 Among the first is the 
concept that insight and awareness of symptoms could 
positively predict drug attitude and ultimately outcome.14,15,17 
Among the latter, generally from clinical trials, there are data 
that switching to newer antipsychotics could favor better 
attitude and ultimately better compliance.25,26 Since their 
original description in the self-report of their experience of 
neuroleptic treatment, the attitude of schizophrenic patients 
toward their pharmacologic treatment was believed to predict 
drug compliance.2,7
Because several factors could predict drug attitude 
to medication, we followed the model proposed by Day 
and colleagues12 to use SEM to explore the relationship 
between clinical variables and DAI in a large sample of 
Table 1 clinical features of the studied sample (n = 227)
Variable
 
Score
Possible range Mean (SD) Range
PAnss – Positive 7 to 49 17.95 (6.01) 7–38
PAnss – negative 7 to 49 25.10 (7.82) 7–45
PAnss – general 16 to 112 45.19 (11.83) 19–76
PAnss – cognitive factors  
(cF) P2 + n5 + n7 + g4 +  
g5 + g11 + g12
7 to 49 21.44 (6.72) 7–40
PAnss – item g12 1 to 7 3.23 (1.50) 1–7
DAi-30 25 to 50 42.00 (5.85) 26–50
gAF 0 to 100 48.83 (11.22) 21–76
Abbreviations: DAi-30, Drug Attitude inventory; gAF, global Assessment of 
Functioning; PAnss, Positive and negative syndrome scale.Patient Preference and Adherence 2009:3 308
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patients with schizophrenia and schizoaffective disorders. 
We used different SEM models, each differing on the basis 
of an a priori hypothesis of the authors about relationship 
between PANNS factors and GAF19,26 that offer different 
clinical considerations. Model 3 assessed GAF separately 
from PANSS factors and ruled out a nontrivial contribution 
of GAF itself (ie, better GAF means a better attitude toward 
medication). When GAF was believed to interact with 
PANSS factors (model 4), PANSS Positive gained more 
attention. As expected insight–cognition does have a higher 
impact on DAI-30 after controlling GAF.
We appreciate that attitude toward medication is 
a complex and multifactorial construct depending on its 
assessment and psychosocial variables as recently reported by 
Day and colleagues.12 Nevertheless, symptom dimensions do 
have a crucial role. Depending on the a priori hypothesis on 
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Figure 1 Hypothesized models with fitted coefficients.
Notes:   The arrows represent the linear equation relationships and it is used to indicate causal flow from one variable to another (direct effects). The arrows with two points 
represent the correlations between groups of variables.
Table 2 Structural equation modeling: Hypothesized models with fitted coefficients
Variables in the model GFI1 Maximum  
likelihood  
estimation
Model  
chi-squared 
p
RMSEA2 
(90% CL)
1.  PAnss and gAF 0.68 2.97 0.0001 0.99 (0.93–1.06)
2.  PAnss, but not gAF 0.61 3.43 0.0001 1.31 (1.23–1.39)
3.    PAnss and gAF with relationship within groups  
of variables
0.76 3.49 0.0001 0.83 (0.78–0.88)
4.    PAnss, gAF and insight (PAnss g12 and cF) with  
relationship between groups of variables
0.99 0.005 = 0.298   0.02 (0–0.18)
Abbreviations: CF, ; CL, ; GAF, Global   Assessment of Functioning; GFI, Goodness-of-fit Index; PANSS, Positive and Negative Syndrome scale; RMSEA, root mean square error.Patient Preference and Adherence 2009:3
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the direction of causal link between the assessed variables, the 
available data could fit with different models. Even though 
the variables we selected do have a clear impact in deter-
mining ATM, we show that the most complex data set does 
have higher GFI in predicting ATM, which demonstrates the 
inherent complexity of the construct. The lack of systematic 
assessment of drug-related side-effects and other qualities of 
life-related variables is a limitation of this study.27 A deeper 
psychopathological and psychosocial analysis could better 
explain the meaning of ATM. This could add more informa-
tion toward intervention aimed to increase compliance.28
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